<DOC>
	<DOCNO>NCT00102141</DOCNO>
	<brief_summary>The objective study evaluate effect Angeliq BP period 8 week postmenopausal woman may benefit hormone replacement therapy ( HRT ) relief vasomotor symptoms hypertension .</brief_summary>
	<brief_title>Effect Angeliq Blood Pressure ( BP ) Postmenopausal Hypertensive Women</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc.Bayer HealthCare Pharmaceuticals , Inc.is sponsor trial .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Have hypertension Are currently take antihypertensive medication Have natural menopause least 1 year prior screen Must require hormone therapy opinion investigator</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Postmenopausal</keyword>
	<keyword>vasomotor symptom</keyword>
	<keyword>essential hypertension</keyword>
</DOC>